2CUREX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.446 SEK | -5.11% |
|
+11.50% | -77.81% |
| 02-29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| 02-22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 7.39M 676K 54.07M | Sales 2022 | 3.37M 308K 24.65M | Capitalization | 143M 13.11M 1.05B |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.65M -132M | Net income 2022 | -29M -2.65M -212M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.67M 534M | Net cash position 2022 | 44.89M 4.1M 328M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB
More press releases
| 1 day | -5.11% | ||
| 1 week | +11.50% | ||
| Current month | +25.99% | ||
| 1 month | +16.15% | ||
| 3 months | -80.00% | ||
| 6 months | -82.85% | ||
| Current year | -77.81% |
1 week
0.36
0.47
1 month
0.300.58
Current year
0.292.79
1 year
0.297.50
3 years
0.2926.50
5 years
0.2931.50
10 years
0.2931.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 31/01/21 | |
Grith Hagel
FOU | Founder | 65 | 31/12/05 |
Ole Thastrup
FOU | Founder | 71 | 31/12/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 31/12/05 |
| Chairman | - | 11-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.446 | -5.11% | 2,840 |
| 25/04/24 | 0.47 | +7.06% | 42,983 |
| 24/04/24 | 0.439 | +9.75% | 2,501 |
| 23/04/24 | 0.4 | +1.27% | 25,491 |
| 22/04/24 | 0.395 | -1.25% | 19,509 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 03:03 pm
More quotes
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -77.81% | 716K | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 383M |
- Stock Market
- Equities
- 2CUREX Stock
